Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients

References

• Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008;123:187–194.
   PubMed Web of Science ®Google Scholar
• Engels EA, Pfeiffer RM, Landgren O, et al. Immunologic and virologic predictors of AIDS-related non-Hodgkin's lymphoma in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr 2010;54:78–84.
   PubMed Web of Science ®Google Scholar
• Lim ST, Roksana K, Nathwani BN, et al. AIDS-related Burkitt's lymphoma versus large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol 2005;23: 4430–4438.
   PubMed Web of Science ®Google Scholar
• Little RF, Pittaluga S, Nicole G, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003;101:4653–4659.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Lee S, Chen MG, et al. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). J Clin Oncol 2004;22:1491–1500.
   PubMed Web of Science ®Google Scholar
• Hoffman C, Wolf E, Wyen C, et al. AIDS associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective. Leuk Lymphoma 2006;47:1872–80.
   PubMed Web of Science ®Google Scholar
• Xicoy B, Ribera JM, Miralles P, et al. Comparison of CHOP treatment with specific short-intensive chemotherapy in AIDS-related Burkitt's lymphoma or leukemia. Med Clin (Barc) 2011;136:323–328.
   PubMed Web of Science ®Google Scholar
• Spina M, Jaeger U, Sparano JA, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin's lymphoma: pooled results from 3 phase 2 trials. Blood 2005;105:1891–1897.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Lee JY, Kaplan LD, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin's lymphoma. Blood 2010;115:3008–3016.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Little R, Wayne AS, et al. Long term outcome of AIDS-related lymphoma treated with abbreviated cycles of EPOCH-R: a prospective study of 40 patients. Blood 2008;112(Suppl. 1):Abstract 3606.
   PubMed Web of Science ®Google Scholar
• Tirelli U, Spina M, Jaeger U, et al. Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study. Recent Results Cancer Res 2002;159:149–153.
   PubMedGoogle Scholar
• Boue F, Gabarre J, Gisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin’s lymphoma. J Clin Oncol 2006;24:4123–4128.
   PubMed Web of Science ®Google Scholar
• Barta SK, Lee JY, Sparano JA, et al. Pooled analysis of AIDS malignancy consortium (AMC) trials evaluating rituximab plus either CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin's lymphoma. Blood 2010;116(Suppl. 1):Abstract 1797.
   PubMed Web of Science ®Google Scholar
• Montoto S, Wilson J, Shaw K, et al. Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma. AIDS 2010;24:851–856.
   PubMed Web of Science ®Google Scholar
• Wang ES, Straus DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 2003;98:1196–1205.
   PubMed Web of Science ®Google Scholar
• Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002;94:1492–1499.
   PubMed Web of Science ®Google Scholar
• Fayad L, Thomas D, Romaguera J. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. Clin Lymphoma Myeloma 2007;8(Suppl. 2):S57–S62.
   Google Scholar
• Suzuki K, Nakazato T, Sanada Y, et al. Successful treatment with hyper-CVAD and highly active anti-retroviral therapy (HAART) for AIDS-related Burkitt lymphoma. Rinsho Ketsueki 2010;51:207–212.
   PubMedGoogle Scholar
• Galicier L, Fieschi C, Borie R, et al. Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study. Blood 2007;110:2846–2854.
   PubMed Web of Science ®Google Scholar
• Oriol A, Ribera JM, Bergua J, et al. High-dose chemotherapy and immunotherapy in adult Burkitt's lymphoma: comparison of results in human immunodeficiency virus-infected and non-infected patients. Cancer 2008;113:117–125.
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Hiddemann W, Baumann A, et al. High survival rate in adult Burkitt's lymphoma/leukemia and diffuse large B cell lymphoma with mediastinal involvement. Blood 2007;110(Suppl. 1): Abstract 518.
   Web of Science ®Google Scholar
• Hoelzer D, Ludwig WD, Thiel E, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996;87:495–508.
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;10:1419–1432.
   Google Scholar
• The International non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection:2006 recommendations of the International AIDS Society-USA panel. JAMA 2006;296:827–843.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: analysis and examples. Br J Cancer 1977;35:1–39.
   PubMed Web of Science ®Google Scholar
• Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34:187–220.
   Google Scholar
• Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin's lymphoma. Cancer 2001;91:155–163.
   PubMed Web of Science ®Google Scholar
• Kaplan LD, Straus DJ, Testa MA, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. N Engl J Med 2006;336:1641–1648.
   Web of Science ®Google Scholar
• Straus DJ, Huang J, Testa MA, et al. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142-low-dose versus standard dose m-BACOD plus granulocyte macrophage colony-stimulating factor. J Clin Oncol 1998;16:3601–3606.
   PubMed Web of Science ®Google Scholar
• Oriol A, Ribera JM, Brunet S, et al. Highly active antiretroviral therapy and outcome of AIDS-related Burkitt's lymphoma or leukemia. Results of the PETHEMA LAL3/97 study. Haematologica 2005;90: 990–992.
   PubMed Web of Science ®Google Scholar
• Oriol A, Ribera JM, Esteve J, et al. Lack of influence of human imunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study.Haematologica 2003;88: 445–453.
   PubMed Web of Science ®Google Scholar
• Kaplan L, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or wtihout rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005;106:1538–1543.
   PubMed Web of Science ®Google Scholar
• Ribera JM, Oriol A, Morgades M, et al. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol 2008;140:411–419.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Bruno Ventre M, Donadoni G, et al. Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma. Br J Haematol 2012;159:252–255.
   PubMed Web of Science ®Google Scholar